Metrion is delighted to announce the appointment of Dr Tom Ashmore as Senior Business Development Director - Europe. In this role, Tom will lead our business development activities across the UK and EU, focusing on driving new business opportunities, nurturing client relationships, and supporting Metrion’s continued growth as a global leader in ion channel drug discovery.
Tom joins Metrion from HistologiX, where he served as Business Development Manager, successfully expanding commercial partnerships and contributing to significant revenue growth. He holds a PhD in Biochemistry and Comparative Physiology from the University of Cambridge, bringing a deep scientific understanding and analytical approach to his client engagement and strategic development work.
With more than a decade of experience in the life sciences sector, Tom has a proven track record of forging long-term partnerships and supporting drug discovery and development pipelines for virtual organisations, small and medium biotechs, and multinational pharmaceutical companies worldwide. His combination of scientific expertise, business acumen, and passion for client success aligns perfectly with Metrion’s mission and values.
Dr Tom Ashmore added: “I’m thrilled to be joining Metrion at such an exciting time for the company. Metrion’s reputation for scientific excellence and innovation in ion channel research is outstanding, and I’m looking forward to helping expand the company’s footprint while continuing to deliver exceptional value to pharma and biotech companies and help them accelerate their discovery timelines.”
Dr Lee Patterson, CEO of Metrion Biosciences, commented: “We are thrilled to welcome Tom Ashmore to Metrion. Tom’s appointment reflects our commitment to deepening our client relationships and advancing Metrion’s reputation as a trusted specialist CRO and leader in ion channel, cardiac safety, and neuroscience screening.”
Welcome to the team, Tom!
Metrion is delighted to announce the appointment of Dr Tom Ashmore as Senior Business Development Director - Europe. In this role, Tom will lead our business development activities across the UK and EU, focusing on driving new business opportunities, nurturing client relationships, and supporting Metrion’s continued growth as a global leader in ion channel drug discovery.
Tom joins Metrion from HistologiX, where he served as Business Development Manager, successfully expanding commercial partnerships and contributing to significant revenue growth. He holds a PhD in Biochemistry and Comparative Physiology from the University of Cambridge, bringing a deep scientific understanding and analytical approach to his client engagement and strategic development work.
With more than a decade of experience in the life sciences sector, Tom has a proven track record of forging long-term partnerships and supporting drug discovery and development pipelines for virtual organisations, small and medium biotechs, and multinational pharmaceutical companies worldwide. His combination of scientific expertise, business acumen, and passion for client success aligns perfectly with Metrion’s mission and values.
Dr Tom Ashmore added: “I’m thrilled to be joining Metrion at such an exciting time for the company. Metrion’s reputation for scientific excellence and innovation in ion channel research is outstanding, and I’m looking forward to helping expand the company’s footprint while continuing to deliver exceptional value to pharma and biotech companies and help them accelerate their discovery timelines.”
Dr Lee Patterson, CEO of Metrion Biosciences, commented: “We are thrilled to welcome Tom Ashmore to Metrion. Tom’s appointment reflects our commitment to deepening our client relationships and advancing Metrion’s reputation as a trusted specialist CRO and leader in ion channel, cardiac safety, and neuroscience screening.”
Welcome to the team, Tom!
Metrion is delighted to announce the appointment of Dr Tom Ashmore as Senior Business Development Director - Europe. In this role, Tom will lead our business development activities across the UK and EU, focusing on driving new business opportunities, nurturing client relationships, and supporting Metrion’s continued growth as a global leader in ion channel drug discovery.
Tom joins Metrion from HistologiX, where he served as Business Development Manager, successfully expanding commercial partnerships and contributing to significant revenue growth. He holds a PhD in Biochemistry and Comparative Physiology from the University of Cambridge, bringing a deep scientific understanding and analytical approach to his client engagement and strategic development work.
With more than a decade of experience in the life sciences sector, Tom has a proven track record of forging long-term partnerships and supporting drug discovery and development pipelines for virtual organisations, small and medium biotechs, and multinational pharmaceutical companies worldwide. His combination of scientific expertise, business acumen, and passion for client success aligns perfectly with Metrion’s mission and values.
Dr Tom Ashmore added: “I’m thrilled to be joining Metrion at such an exciting time for the company. Metrion’s reputation for scientific excellence and innovation in ion channel research is outstanding, and I’m looking forward to helping expand the company’s footprint while continuing to deliver exceptional value to pharma and biotech companies and help them accelerate their discovery timelines.”
Dr Lee Patterson, CEO of Metrion Biosciences, commented: “We are thrilled to welcome Tom Ashmore to Metrion. Tom’s appointment reflects our commitment to deepening our client relationships and advancing Metrion’s reputation as a trusted specialist CRO and leader in ion channel, cardiac safety, and neuroscience screening.”
Welcome to the team, Tom!